v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Revenue $ 288,945 $ 883,001 $ 799,240
Operating expenses:      
Cost of revenue 148,743 168,957 140,561
Selling, general and administrative 151,390 129,259 100,064
Research and development 17,280 18,369 15,219
Change in estimated fair value of contingent consideration (3,286) (7,800) 0
Restructuring 6,466 0 0
Gain on sale of business 0 0 (11,249)
Total operating expenses 320,593 308,785 244,595
(Loss) income from operations (31,648) 574,216 554,645
Other income (expense):      
Interest expense (45,892) (20,414) (30,260)
Interest income 27,727 2,338 0
Loss on extinguishment of debt 0 (208) 0
Change in payable to related parties pursuant to the Tax Receivable Agreement 668,886 (4,102) 6,101
Other (expense) income (1,337) (358) 279
Income before income taxes 617,736 551,472 530,765
Income tax expense 756,111 60,809 61,515
Net (loss) income (138,375) 490,663 469,250
Net (loss) income attributable to non-controlling interests (19,346) 270,458 287,213
Net (loss) income attributable to Maravai LifeSciences Holdings, Inc. $ (119,029) $ 220,205 $ 182,037
Net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.:      
Basic (in usd per share) $ (0.90) $ 1.67 $ 1.59
Diluted (in usd per share) $ (0.90) $ 1.67 $ 1.56
Weighted average number of Class A common shares outstanding:      
Basic (in shares) 131,919 131,545 114,791
Diluted (in shares) 131,919 255,323 257,803

Source